284 related articles for article (PubMed ID: 27999358)
21. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis.
Chung WH; Hung SI
J Dermatol Sci; 2012 Jun; 66(3):190-6. PubMed ID: 22541332
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis.
Hasegawa A; Abe R
F1000Res; 2020; 9():. PubMed ID: 32595945
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of cytotoxic proteins correlates with liver function impairment in patients with drug reaction with eosinophilia and systemic symptoms (DRESS).
Yang F; Chen SA; Wu X; Zhu Q; Luo X
Eur J Dermatol; 2018 Feb; 28(1):13-25. PubMed ID: 29521632
[TBL] [Abstract][Full Text] [Related]
24. Use of infliximab in toxic epidermal necrolysis: a still opened challenge.
Ganzetti G; Campanati A; Simonetti O; Giuliodori K; Giangiacomi M; Lemme G; Offidani A
G Ital Dermatol Venereol; 2015 Aug; 150(4):467-71. PubMed ID: 25394212
[TBL] [Abstract][Full Text] [Related]
25. Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features.
Cho YT; Lin JW; Chen YC; Chang CY; Hsiao CH; Chung WH; Chu CY
J Am Acad Dermatol; 2014 Mar; 70(3):539-48. PubMed ID: 24388722
[TBL] [Abstract][Full Text] [Related]
26. Severe cutaneous adverse reactions to drugs.
Chia FL; Leong KP
Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):304-9. PubMed ID: 17620821
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.
Viard I; Wehrli P; Bullani R; Schneider P; Holler N; Salomon D; Hunziker T; Saurat JH; Tschopp J; French LE
Science; 1998 Oct; 282(5388):490-3. PubMed ID: 9774279
[TBL] [Abstract][Full Text] [Related]
28. [Stevens-Johnson syndrome and toxic epidermal necrolysis].
Kaur-Knudsen D; Zachariae C; Thomsen SF
Ugeskr Laeger; 2013 Dec; 175(50):3096-9. PubMed ID: 24629532
[TBL] [Abstract][Full Text] [Related]
29. Toxic epidermal necrolysis.
Pereira FA; Mudgil AV; Rosmarin DM
J Am Acad Dermatol; 2007 Feb; 56(2):181-200. PubMed ID: 17224365
[TBL] [Abstract][Full Text] [Related]
30. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding.
French LE
Allergol Int; 2006 Mar; 55(1):9-16. PubMed ID: 17075281
[TBL] [Abstract][Full Text] [Related]
31. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding.
French LE; Trent JT; Kerdel FA
Int Immunopharmacol; 2006 Apr; 6(4):543-9. PubMed ID: 16504917
[TBL] [Abstract][Full Text] [Related]
32. Distinguishing between erythema multiforme major and Stevens-Johnson syndrome/toxic epidermal necrolysis immunopathologically.
Iwai S; Sueki H; Watanabe H; Sasaki Y; Suzuki T; Iijima M
J Dermatol; 2012 Sep; 39(9):781-6. PubMed ID: 22458564
[TBL] [Abstract][Full Text] [Related]
33. Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis.
Tohyama M; Watanabe H; Murakami S; Shirakata Y; Sayama K; Iijima M; Hashimoto K
Br J Dermatol; 2012 Feb; 166(2):322-30. PubMed ID: 21936856
[TBL] [Abstract][Full Text] [Related]
34. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment.
Schwartz RA; McDonough PH; Lee BW
J Am Acad Dermatol; 2013 Aug; 69(2):187.e1-16; quiz 203-4. PubMed ID: 23866879
[TBL] [Abstract][Full Text] [Related]
35. Stevens-Johnson syndrome and toxic epidermal necrolysis.
Borchers AT; Lee JL; Naguwa SM; Cheema GS; Gershwin ME
Autoimmun Rev; 2008 Sep; 7(8):598-605. PubMed ID: 18603022
[TBL] [Abstract][Full Text] [Related]
36. An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children.
Koh MJ; Tay YK
Curr Opin Pediatr; 2009 Aug; 21(4):505-10. PubMed ID: 19474732
[TBL] [Abstract][Full Text] [Related]
37. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand.
Abe R; Shimizu T; Shibaki A; Nakamura H; Watanabe H; Shimizu H
Am J Pathol; 2003 May; 162(5):1515-20. PubMed ID: 12707034
[TBL] [Abstract][Full Text] [Related]
38. Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study.
Paquet P; Jennes S; Rousseau AF; Libon F; Delvenne P; Piérard GE
Burns; 2014 Dec; 40(8):1707-12. PubMed ID: 24726294
[TBL] [Abstract][Full Text] [Related]
39. Clinical and microscopic characteristics of canine toxic epidermal necrolysis.
Banovic F; Olivry T; Bazzle L; Tobias JR; Atlee B; Zabel S; Hensel N; Linder KE
Vet Pathol; 2015 Mar; 52(2):321-30. PubMed ID: 24907312
[TBL] [Abstract][Full Text] [Related]
40. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: a comparative review.
Yager JA
Vet Dermatol; 2014 Oct; 25(5):406-e64. PubMed ID: 24990284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
